ATX-304 (formerly O304) vs SANA (MVD1)

ATX-304 (formerly O304) (B-tier) vs SANA (MVD1) (B-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.

ATX-304 (formerly O304) — tier B

an investigational oral AMPK activator with one small randomized diabetes trial, a newer obesity pilot, and an animal pharmacokinetic curve that cannot establish a human dosing interval.

the AMPK pharmacology and early human signal are real, but the clinical file is too small and short to support the certainty implied by the current research-chemical market.

65 participants in the published 28-day randomized trial · half-life human terminal half-life not published; approximately 11 hours shown only as a low-confidence mouse apparent-decline proxy · weight loss

SANA (MVD1) — tier B

an investigational nitroalkene small molecule that targets creatine-kinase-dependent thermogenesis, with mouse fat-loss data, a small exploratory 15-day human weight signal, and a high-dose renal safety signal in phase 1.

SANA has a defined identity, a novel creatine-thermogenesis mechanism, mouse efficacy, and direct human PK, but the phase 1 renal signal makes dose-dependent safety the central fact.

41 participants across the first-in-human phase 1 program · half-life approximately 1.6 to 2.0 hours in the first-in-human oral phase 1 study · weight loss

at a glance

• ATX-304 (formerly O304): tier B · 65 participants in the published 28-day randomized trial
• SANA (MVD1): tier B · 41 participants across the first-in-human phase 1 program

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.